We took Mr. M B Chinappa, CFO of Syngene, on a non-deal roadshow to Singapore, Hong Kong and Taiwan, arranging meetings with over 25 FIIs. Syngene manages to roll forward 90-95% of its existing business into the next year due to its steady business model and strong relationships with existing clients. Syngene has guided for revenue growth of >20% per annum until FY18, along with stable EBITDA and PAT margins. We expect it to achieve this guidance. We expect the company to continue commanding premium multiples, given its robust revenue growth (double the pace of industry growth), attractive margin profile (EBITDA...